Breast tumors from CHEK2 1100delC-mutation carriers: Genomic landscape and clinical implications

Breast Cancer Research

Volumn 13, Issue 5, 2011, Pages

  Muranen, Taru A ^a,b   Greco, Dario ^a   Fagerholm, Rainer ^a   Kilpivaara, Outi ^a   Kämpjärvi, Kati ^a   Aittomäki, Kristiina ^a   Blomqvist, Carl ^a   Heikkilä, Päivi ^a   Borg, Åke ^c   Nevanlinna, Heli ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; CALCOCO1 PROTEIN, HUMAN; CARRIER PROTEIN; CHLORIDE CHANNEL; CLCA1 PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; BAYES THEOREM; BREAST CANCER; CANCER MORTALITY; CANCER RELAPSE; CHROMOSOME 1; CHROMOSOME 12Q; CHROMOSOME 16P; CHROMOSOME 17P; CHROMOSOME 19P; CHROMOSOME 8P; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE LOCUS; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC GAIN; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; SURVIVAL TIME; TUMOR GROWTH; BREAST TUMOR; FEMALE; GENE DELETION; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; MORTALITY; MUTATION; WNT SIGNALING PATHWAY;

BAYES THEOREM; BREAST NEOPLASMS; CARRIER PROTEINS; CHLORIDE CHANNELS; CHROMOSOMES, HUMAN, PAIR 1; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MUTATION; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE DELETION; WNT SIGNALING PATHWAY;

EID: 80054996659     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3015     Document Type: Article

References (94)

1. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 10.1186/1471-2164-7-96, 1468408, 16643655.
2. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
3. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
4. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
5. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
6. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272. 10.1093/jnci/djj052, 16478745.
7. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
8. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239. 10.1186/1471-2164-9-239, 2423197, 18498629.
9. Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science 2002, 297:565-569. 10.1126/science.297.5581.565, 12142527.
10. Murnane JP. Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res 2010, 70:4255-4259. 10.1158/0008-5472.CAN-09-4357, 2967490, 20484032.
11. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature 2009, 460:278-282. 10.1038/nature08136, 2743290, 19506557.
12. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992, 258:818-821. 10.1126/science.1359641, 1359641.
13. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998, 20:207-211. 10.1038/2524, 9771718.
14. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringner M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP, Kallioniemi A. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002, 62:6240-6245.
15. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, . Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329. 10.1093/annonc/mdp322, 2720818, 19535820, Panel members.
16. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010, 7:e1000279. 10.1371/journal.pmed.1000279, 2876119, 20520800.
17. Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee P, Godwin AK, Hogervorst FB, Couch F, Grimmond S, Flanagan JM, Khanna K, Simpson PT, Lakhani SR, Chenevix-Trench G. kConFab Investigators Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 2010, 123:661-677. 10.1007/s10549-009-0653-1, 19960244, kConFab Investigators.
18. Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkila P, Aittomaki K, Blomqvist C, Loman N, Malmstrom P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010, 12:R42. 10.1186/bcr2596, 2917037, 20576095.
19. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
20. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
21. van Beers EH, van Welsem T, Wessels LF, Li Y, Oldenburg RA, Devilee P, Cornelisse CJ, Verhoef S, Hogervorst FB, van't Veer LJ, Nederlof PM. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005, 65:822-827.
22. CHEK2 Breast Cancer Case-Control Consortium CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004, 74:1175-1182. 1182081, 15122511, CHEK2 Breast Cancer Case-Control Consortium.
23. Fletcher O, Johnson N, Dos Santos Silva I, Kilpivaara O, Aittomaki K, Blomqvist C, Nevanlinna H, Wasielewski M, Meijers-Heijerboer H, Broeks A, Schmidt MK, Van't Veer LJ, Bremer M, Dork T, Chekmariova EV, Sokolenko AP, Imyanitov EN, Hamann U, Rashid MU, Brauch H, Justenhoven C, Ashworth A, Peto J. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomarkers Prev 2009, 18:230-234. 10.1158/1055-9965.EPI-08-0416, 2727696, 19124502.
24. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286:2528-2531. 10.1126/science.286.5449.2528, 10617473.
25. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002, 71:432-438. 10.1086/341943, 379177, 12094328.
26. Staalesen V, Falck J, Geisler S, Bartkova J, Borresen-Dale AL, Lukas J, Lillehaug JR, Bartek J, Lonning PE. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 2004, 23:8535-8544. 10.1038/sj.onc.1207928, 15361853.
27. Anczukow O, Ware MD, Buisson M, Zetoune AB, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S. Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?. Hum Mutat 2008, 29:65-73. 10.1002/humu.20590, 17694537.
28. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 2006, 25:5912-5919. 10.1038/sj.onc.1209877, 16998506.
29. Stolz A, Ertych N, Kienitz A, Vogel C, Schneider V, Fritz B, Jacob R, Dittmar G, Weichert W, Petersen I, Bastians H. The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol 2010, 12:492-499. 10.1038/ncb2051, 20364141.
30. Chen LC, Kurisu W, Ljung BM, Goldman ES, Moore D, Smith HS. Heterogeneity for allelic loss in human breast cancer. J Natl Cancer Inst 1992, 84:506-510. 10.1093/jnci/84.7.506, 1312176.
31. Williams LH, Choong D, Johnson SA, Campbell IG. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res 2006, 12:6967-6972. 10.1158/1078-0432.CCR-06-1770, 17145815.
32. Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003, 63:8153-8157.
33. Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams RD, Bevan S, Bishop K, McGuire S, Houlston RS, Eeles RA. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer 2002, 87:1445-1448. 10.1038/sj.bjc.6600637, 2376278, 12454775.
34. de Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 2004, 41:731-735. 10.1136/jmg.2004.019737, 1735606, 15466005.
35. Kilpivaara O, Bartkova J, Eerola H, Syrjakoski K, Vahteristo P, Lukas J, Blomqvist C, Holli K, Heikkila P, Sauter G, Kallioniemi OP, Bartek J, Nevanlinna H. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 2005, 113:575-580. 10.1002/ijc.20638, 15472904.
36. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 2007, 25:64-69.
37. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res 2007, 9:R26. 10.1186/bcr1668, 1868917, 17428320.
38. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lonning PE. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008, 3:e3062. 10.1371/journal.pone.0003062, 2518116, 18725978.
39. Gene Expression Omnibus , http://www.ncbi.nlm.nih.gov/geo/
40. Jonsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, de Jong P, Oredsson S, Ringner M, Hoglund M, Borg A. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007, 46:543-558. 10.1002/gcc.20438, 17334996.
41. van de Wiel MA, Kim KI, Vosse SJ, van Wieringen WN, Wilting SM, Ylstra B. CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 2007, 23:892-894. 10.1093/bioinformatics/btm030, 17267432.
42. van de Wiel MA, van Wieringen WN. CGHregions: dimension reduction for array CGH data with minimal information loss. Cancer Inform 2007, 3:55-63. 2675846, 19455235.
43. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article3.
44. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods 2003, 31:265-273. 10.1016/S1046-2023(03)00155-5, 14597310.
45. Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK. A comparison of background correction methods for two-colour microarrays. Bioinformatics 2007, 23:2700-2707. 10.1093/bioinformatics/btm412, 17720982.
46. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjakoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomaki K, von Smitten K, Heikkila P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008, 40:844-853. 10.1038/ng.155, 18511948.
47. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
48. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S, . AmiGO Hub, Web Presence Working Group AmiGO: online access to ontology and annotation data. Bioinformatics 2009, 25:288-289. 10.1093/bioinformatics/btn615, 2639003, 19033274, AmiGO Hub, Web Presence Working Group.
49. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology: The Gene Ontology Consortium. Nat Genet 2000, 25:25-29. 10.1038/75556, 3037419, 10802651.
50. The Gene Ontology. , http://www.geneontology.org/
51. Lukes L, Crawford NP, Walker R, Hunter KW. The origins of breast cancer prognostic gene expression profiles. Cancer Res 2009, 69:310-318. 10.1158/0008-5472.CAN-08-3520, 2613551, 19118016.
52. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000, 92:1529-1531. 10.1093/jnci/92.18.1529, 10995809.
53. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
54. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA, Miller LD. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006, 66:10292-10301. 10.1158/0008-5472.CAN-05-4414, 17079448.
55. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedren S, Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005, 7:R953-64. 10.1186/bcr1325, 1410752, 16280042.
56. Yang CK, Kim JH, Li H, Stallcup MR. Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1. J Biol Chem 2006, 281:3389-3397. 1626527, 16344550.
57. Miksicek RJ, Myal Y, Watson PH, Walker C, Murphy LC, Leygue E. Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. Cancer Res 2002, 62:2736-2740.
58. Skliris GP, Hube F, Gheorghiu I, Mutawe MM, Penner C, Watson PH, Murphy LC, Leygue E, Myal Y. Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology 2008, 52:355-369. 10.1111/j.1365-2559.2007.02955.x, 2253716, 18269587.
59. Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, Wang W, Kashanchi F, Shiekhattar R. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000, 102:257-265. 10.1016/S0092-8674(00)00030-1, 10943845.
60. Schorr K, Li M, Krajewski S, Reed JC, Furth PA. Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia 1999, 4:153-164. 10.1023/A:1018773123899, 10426394.
61. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408:307-310. 10.1038/35042675, 11099028.
62. Cooke SL, Pole JC, Chin SF, Ellis IO, Caldas C, Edwards PA. High-resolution array CGH clarifies events occurring on 8p in carcinogenesis. BMC Cancer 2008, 8:288. 10.1186/1471-2407-8-288, 2576333, 18840272.
63. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 1999, 79:1468-1474. 10.1038/sj.bjc.6690234, 2362732, 10188892.
64. Gruber AD, Schreur KD, Ji HL, Fuller CM, Pauli BU. Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland. Am J Physiol 1999, 276:C1261-70.
65. Li X, Cowell JK, Sossey-Alaoui K. CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. Oncogene 2004, 23:1474-1480. 10.1038/sj.onc.1207249, 14973555.
66. Katoh M. WNT and FGF gene clusters (review). Int J Oncol 2002, 21:1269-1273.
67. Dale TC, Weber-Hall SJ, Smith K, Huguet EL, Jayatilake H, Gusterson BA, Shuttleworth G, O'Hare M, Harris AL. Compartment switching of WNT-2 expression in human breast tumors. Cancer Res 1996, 56:4320-4323.
68. Watanabe O, Imamura H, Shimizu T, Kinoshita J, Okabe T, Hirano A, Yoshimatsu K, Konno S, Aiba M, Ogawa K. Expression of twist and wnt in human breast cancer. Anticancer Res 2004, 24:3851-3856.
69. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 2007, 9:R63. 10.1186/bcr1769, 2242658, 17897439.
70. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005, 17:548-558. 10.1016/j.ceb.2005.08.001, 16098727.
71. Cowling VH, Cole MD. Turning the tables: Myc activates Wnt in breast cancer. Cell Cycle 2007, 6:2625-2627. 10.4161/cc.6.21.4880, 17726380.
72. Young JM, Endicott RM, Parghi SS, Walker M, Kidd JM, Trask BJ. Extensive copy-number variation of the human olfactory receptor gene family. Am J Hum Genet 2008, 83:228-242. 10.1016/j.ajhg.2008.07.005, 2495065, 18674749.
73. Hasin Y, Olender T, Khen M, Gonzaga-Jauregui C, Kim PM, Urban AE, Snyder M, Gerstein MB, Lancet D, Korbel JO. High-resolution copy-number variation map reflects human olfactory receptor diversity and evolution. PLoS Genet 2008, 4:e1000249. 10.1371/journal.pgen.1000249, 2570968, 18989455.
74. Keller A, Zhuang H, Chi Q, Vosshall LB, Matsunami H. Genetic variation in a human odorant receptor alters odour perception. Nature 2007, 449:468-472. 10.1038/nature06162, 17873857.
75. Neuhaus EM, Zhang W, Gelis L, Deng Y, Noldus J, Hatt H. Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem 2009, 284:16218-16225. 10.1074/jbc.M109.012096, 2713531, 19389702.
76. Firestein S. How the olfactory system makes sense of scents. Nature 2001, 413:211-218. 10.1038/35093026, 11557990.
77. Dreyer WJ. The area code hypothesis revisited: olfactory receptors and other related transmembrane receptors may function as the last digits in a cell surface code for assembling embryos. Proc Natl Acad Sci USA 1998, 95:9072-9077. 10.1073/pnas.95.16.9072, 33877, 9689035.
78. Feinstein P, Mombaerts P. A contextual model for axonal sorting into glomeruli in the mouse olfactory system. Cell 2004, 117:817-831. 10.1016/j.cell.2004.05.011, 15186781.
79. Feldmesser E, Olender T, Khen M, Yanai I, Ophir R, Lancet D. Widespread ectopic expression of olfactory receptor genes. BMC Genomics 2006, 7:121. 10.1186/1471-2164-7-121, 1508154, 16716209.
80. Sodha N, Mantoni TS, Tavtigian SV, Eeles R, Garrett MD. Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. Cancer Res 2006, 66:8966-8970. 10.1158/0008-5472.CAN-06-1990, 16982735.
81. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165. 10.1158/1078-0432.CCR-07-4756, 18698033.
82. Smyth GK, Yang YH, Speed T. Statistical issues in cDNA microarray data analysis. Methods Mol Biol 2003, 224:111-136.
83. Smyth GK. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor 2005, 397-420. New York: Springer, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W.
84. R Development Core Team R: A Language and Environment for Statistical Computing. 2010, R Foundation for Statistical computing, Vienna, Austria, R Development Core Team.
85. Silver JD, Ritchie ME, Smyth GK. Microarray background correction: maximum likelihood estimation for the normal-exponential convolution. Biostatistics 2009, 10:352-363. 2648902, 19068485.
86. Staaf J, Jonsson G, Ringner M, Vallon-Christersson J. Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics 2007, 8:382. 10.1186/1471-2164-8-382, 2190775, 17953745.
87. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 2002, 3:SOFTWARE0003. 139402, 12186655, 12186655.
88. Vallon-Christersson J, Nordborg N, Svensson M, Hakkinen J. BASE: 2nd generation software for microarray data management and analysis. BMC Bioinformatics 2009, 10:330. 10.1186/1471-2105-10-330, 2768720, 19822003.
89. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004, 5:557-572. 10.1093/biostatistics/kxh008, 15475419.
90. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007, 23:657-663. 10.1093/bioinformatics/btl646, 17234643.
91. Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, Fujita PA, Diekhans M, Smith KE, Rosenbloom KR, Raney BJ, Pohl A, Pheasant M, Meyer LR, Learned K, Hsu F, Hillman-Jackson J, Harte RA, Giardine B, Dreszer TR, Clawson H, Barber GP, Haussler D, Kent WJ. The UCSC Genome Browser database: update 2010. Nucleic Acids Res 2010, 38:D613-9. 10.1093/nar/gkp939, 2808870, 19906737.
92. Van Wieringen WN, Van De Wiel MA, Ylstra B. Weighted clustering of called array CGH data. Biostatistics 2008, 9:484-500.
93. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, Tanner M, Tirkkonen M, Isola J. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis: a study of 305 tumors by comparative genomic hybridization. Cancer Res 2003, 63:8861-8868.
94. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541. 10.1016/j.ccr.2006.10.009, 17157792.